Literature DB >> 7775826

Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression.

M A Davis1, H Y Tang, J Maybaum, T S Lawrence.   

Abstract

Recent evidence casts doubt on the hypotheses that fluoropyrimidine-mediated radiosensitization is related to cytotoxicity or to cell cycle redistribution into the G1/S boundary. We hypothesized that cells that are capable of progressing into S phase in the presence of fluorodeoxyuridine may also be more susceptible to radiation-induced damage. To test this hypothesis, fluorodeoxyuridine (FdUrd)-treated HT29 human colon cancer cells were separated by centrifugal elutriation into four fractions (1-4) containing a range of cells from those at the G1/S boundary (fraction 1) to those which had progressed approximately 11% into S phase (fraction 4). We found that fraction 4 cells showed significantly greater radiosensitization than fraction 1 cells. We also compared the effects of fluorodeoxyuridine on HT29 and SW620 human colon cancer cells. We found that, in contrast with HT29 cells, SW620 cells arrested at the G1/S boundary and were minimally radiosensitized. Finally, we found that an increase in sensitivity was correlated with a decrease in the rate of repair of DNA double-strand and single-strand breaks (assessed by asymmetric field inversion gel electrophoresis and alkaline elution respectively). These findings are consistent with the hypothesis that fluorodeoxyuridine-mediated radiosensitization depends on S phase progression and a decreased ability to repair radiation-induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775826     DOI: 10.1080/09553009514550621

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  4 in total

1.  HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells.

Authors:  M D Axelson; M A Davis; S P Ethier; T S Lawrence
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.

Authors:  Sheryl A Flanagan; Christina M Krokosky; Sudha Mannava; Mikhail A Nikiforov; Donna S Shewach
Journal:  Mol Pharmacol       Date:  2008-06-05       Impact factor: 4.436

Review 3.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

4.  Short hairpin RNA suppression of thymidylate synthase produces DNA mismatches and results in excellent radiosensitization.

Authors:  Sheryl A Flanagan; Kristin S Cooper; Sudha Mannava; Mikhail A Nikiforov; Donna S Shewach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-03       Impact factor: 7.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.